Colonial Trust Advisors’s ImmunityBio IBRX Stock Holding History

Colonial Trust Advisors’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$47.5K	Hold	5,425	–	–	﹤0.01%	374
2026 Q1	$41.6K	Buy	5,425 +5,000	+1,176%	+$34.2K	﹤0.01%	368
2025 Q4	$842	Hold	425	–	–	﹤0.01%	663
2025 Q3	$1.05K	Hold	425	–	–	﹤0.01%	639
2025 Q2	$1.12K	Hold	425	–	–	﹤0.01%	650
2025 Q1	$1.28K	Hold	425	–	–	﹤0.01%	634
2024 Q4	$1.09K	Hold	425	–	–	﹤0.01%	634
2024 Q3	$1.58K	Hold	425	–	–	﹤0.01%	693
2024 Q2	$2.69K	Hold	425	–	–	﹤0.01%	663
2024 Q1	$2.28K	Hold	425	–	–	﹤0.01%	785
2023 Q4	$2.13K	Hold	425	–	–	﹤0.01%	707
2023 Q3	$718	Hold	425	–	–	﹤0.01%	797
2023 Q2	$1.18K	Hold	425	–	–	﹤0.01%	786
2023 Q1	$774	Hold	425	–	–	﹤0.01%	811
2022 Q4	$2.15K	Buy	+425	New	+$2.33K	﹤0.01%	715

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Colonial Trust Advisors's IBRX Position: Q2 2026 in Review

Colonial Trust Advisors held its ImmunityBio (IBRX) position steady in Q2 2026 at 5,425 shares worth $47.5K. The position accounts for ﹤0.01% of the portfolio, ranked #374.

Colonial Trust Advisors first reported a position in IBRX in Q4 2022 and has held it in 15 quarters since. 404 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

Colonial Trust Advisors held 5,425 shares of ImmunityBio worth $47.5K as of Q2 2026.
Colonial Trust Advisors left its ImmunityBio share count unchanged in Q2 2026.
ImmunityBio made up ﹤0.01% of Colonial Trust Advisors's portfolio in Q2 2026, its #374 holding.
Colonial Trust Advisors first reported a position in ImmunityBio in Q4 2022 and has held it in 15 quarters since.
404 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Colonial Trust Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.